Analyst Price Target is $5.00
▲ +116.45% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Brainstorm Cell Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 116.45% upside from the last price of $2.31.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in Brainstorm Cell Therapeutics. This rating has held steady since December 2022, when it changed from a Hold consensus rating.
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.